

Allergan plc  
Form 8-K  
November 01, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): October 31, 2018 (October 31, 2018)**

**ALLERGAN PLC**

**(Exact Name of Registrant as Specified in Charter)**

|   |  |   |
|---|--|---|
| <b>Ireland</b><br><b>(State or Other Jurisdiction</b> | <b>001-36867</b><br><b>(Commission</b> | <b>98-1114402</b><br><b>(IRS Employer</b> |
| <b>of Incorporation)</b>                              | <b>File Number)</b>                    | <b>Identification No.)</b>                |
| <b>Clonshaugh Business and Technology Park</b>        |  |   |

Edgar Filing: Allergan plc - Form 8-K

**Coolock, Dublin, D17 E400, Ireland**

**(Address of Principal Executive Offices)**

**(862) 261-7000**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On October 31, 2018, Allergan plc (the Company) posted an Investor FAQ to the Company's investor relations section of its website. The Investor FAQ is responsive to general investor inquiries that the Company has been receiving in connection with its October 30, 2018 earnings release and conference call. A copy of the Investor FAQ is attached hereto as an Exhibit 99.1.

The information in Item 7.01 of this Current Report on this Form 8-K is being furnished to the U.S. Securities and Exchange Commission and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <b>Exhibit</b> | <b>Description of Exhibit</b> |
|----------------|-------------------------------|
|----------------|-------------------------------|

|              |                     |
|--------------|---------------------|
| Exhibit 99.1 | <u>Investor FAQ</u> |
|--------------|---------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 31, 2018

Allergan plc

By: /s/ A. Robert D. Bailey  
A. Robert D. Bailey  
EVP and Chief Legal Officer and Corporate  
Secretary